CervoMed Inc (CRVO)

CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)June 18, 2026 10:08 AM
IH Market News CervoMed Inc. (NASDAQ:CRVO) shares climbed 20% on Thursday after the company announced it had received a notice of allowance from the U.S. Patent and Trademark Office for a new patent covering the use of its lead drug candidate, neflamapimod, in the treatment of dementia with Lewy bodies (DLB). The development strengthens the biotechnology company’s intellectual property portfolio and could provide long-term protection for a key component of its clinical strategy. Patent Targets Specific DLB Patient Population The newly allowed patent relates to the treatment of dementia with Lewy bodies in patients who do not exhibit significant Alzheimer’s disease-related tau pathology, a group often referred to as having “pure DLB.” According to the company, the patent is expected to remain in force until at least 2042, with the possibility of additional protection through future patent term extensions. Strengthening Long-Term Commercial Position CervoMed said the intellectual property is designed to support its approach to treating patients with pure DLB, a subgroup that can be identified through biomarkers such as plasma pTau levels or advanced brain imaging techniques. The company believes this targeted strategy could help differentiate neflamapimod as development progresses and potentially strengthen its future commercial position if approved. Focus on Age-Related Neurological Disorders CervoMed is a clinical-stage biotechnology company focused on developing therapies for age-related neurodegenerative diseases and other brain disorders. Neflamapimod remains one of the company’s key development programmes as it seeks to address significant unmet medical needs in neurological care. Limited Treatment Options for Dementia with Lewy Bodies Dementia with Lewy bodies is one of the most common forms of progressive dementia, yet treatment options remain limited. CervoMed noted that there are currently no approved therapies specifically indicated for DLB in either the United States or the European Union, highlighting the potential importance of new treatment approaches for patients affected by the condition. The patent news was welcomed by investors, who viewed the additional intellectual property protection as a positive step for the company’s long-term development strategy and value proposition. CervoMed stock priceThe post CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO) appeared first on US Editors. Original: CervoMed Shares Surge After Securing U.S. Patent Protection for Dementia Therapy (CRVO)

CRVO.............................p/m

CRVO.........................................https://stockcharts.com/sc3/ui/?s=CRVO&p=w&b=5&g=0&id=p86431144783

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

April 7, 2026

Link article

====================

CRVO Institutional Holdings
Ownership Summary
Institutional Ownership 23.68%
Total Shares Outstanding (millions) 9
Total Value of Holdings (millions) $9

Active Positions | Holders | Shares
Increased Positions | 20 | 183,097
Decreased Positions | 21 | 133,234
Held Positions | 12 |1,876,219
Total Institutional Shares | 53 | 2,192,550

https://www.nasdaq.com/market-activity/stocks/crvo/institutional-holdings

$CERV 🗞️

I like the direction and movement here. Chart would indicate over $11 coming, when? I don't know

AWM Investment Company, Inc. filed a SCHEDULE 13G on 5/7/2025 for 863,200 shares of CervoMed Inc. (9.9 %).

https://www.otcmarkets.com/filing/html?id=18442194&guid=eeV-kFzAdOPedth

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC)

Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD™ 2025 demonstrates improvements on endpoints measuring cognitive fluctuations and working memory

The results demonstrate proof-of-concept for neflamapimod as a treatment for dementia with Lewy bodies (DLB)

Boston – April 2, 2025 – CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that investigators plan to present results, including new results, from the Extension phase of the Phase 2b RewinD-LB study that show neflamapimod demonstrated a clinically meaningful effect on slowing clinical progression in patients with DLB in an oral presentation during the 19th International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurologic Disorders (AP/PD™) on Saturday, April 5, 2025.

“The RewinD-LB Extension phase results for neflamapimod are highly encouraging. We are seeing a clear and meaningful effect on clinical worsening over time in patients with DLB, as assessed by CDR-SB and CGIC, which is further supported by positive data across several additional clinical endpoints,” stated Stephen Gomperts, MD, PhD, Associate Professor of Neurology at Harvard Medical School, Director, Lewy Body Dementia Unit at the Massachusetts General Hospital and site Principal Investigator for the RewinD-LB study. “Importantly, these results validate and replicate prior clinical trial results and are consistent with the scientific hypothesis that neflamapimod can provide clinical benefit by arresting the loss of cholinergic neuron function in the basal forebrain.”

“The presentation of the Extension phase data at AD/PD™ 2025 is an opportunity to share our findings and engage deeply with the DLB medical community as we plan for pivotal development and work to bring neflamapimod to patients as rapidly as possible,” said John Alam, MD, Co-Principal Investigator of the RewinD-LB study and CEO of CervoMed. “The positive findings across the primary outcome measure and multiple additional clinically important endpoints evaluated in the first 16 weeks of the Extension phase strengthen our belief that neflamapimod has the potential to be a transformative therapy for patients with DLB.”

16-Week Results from the Extension Phase of the Phase 2b RewinD-LB Study

Overview

Of the 159 participants randomized in the initial 16-week double-blind, placebo-controlled phase (Initial phase) of the study, 152 completed the Initial phase and 149 entered the extension phase (Extension phase), during which all participants received neflamapimod. As previously announced, during the Extension phase, 55 participants continued to receive the same batch of capsules (Old Capsules) utilized in the Initial phase of the study, while 94 participants received a new batch of capsules (New Capsules) for at least 8 weeks during the Extension phase, approximately half of which received only the New Capsules. In the Initial phase of the study, there were no discernible differences in clinical outcome between the neflamapimod (administered in Old Capsules) and placebo, which was hypothesized to be the result of sub-therapeutic plasma drug concentrations observed with the Old Capsules.

The New Capsules achieved target plasma drug concentrations, which has allowed CervoMed and clinical investigators to compare clinical outcomes between participants receiving the New Capsules (representing an active drug arm) and the Old Capsules (representing a control arm), as well as analyses that compared New Capsules administered during the Extension phase to placebo during the Initial phase of the study. For the comparison to placebo, the Old Capsules served as an important negative control. Participants and site personnel were blinded as to whether New or Old Capsules were being dispensed during the first 16 weeks of the Extension.

Positive effects seen with the New Capsules of neflamapimod compared to controls on multiple clinical endpoints:

Improvement on primary outcome measures, change in CDR-SB, with the New Capsules both vs. Old Capsules (p

$CRVO if we didn't have two big down days in the general market this would have been 15 and on the way to 20 dollars by end of next week. Either way, this is buy the dips with both hands.

I agree...stk gaining nicely this am..

CRVO is getting ready to rock this session going into this week.

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

https://ih.advfn.com/stock-market/NASDAQ/cervomed-CRVO/stock-news/95767405/investigators-to-present-clinical-trial-results-sh

Something is definitely brewing with this one. This is one of those that needs eyes glued to it and every big dip is a must. I seriously believe this is a must go up at some point.

Gearing up.

CRVO is going to run hard one of these days.

Watch this thing rocket in the coming days. Hold for massive run that is brewing.

Big run coming next week.

The simple rule on trading strategy is, one must always do DD. Needless to say, found a little nugget on this baby, the current directors and officers are the founders of $VRTX, which trades on Nasdaq above $500 dollars at a 100 billion market cap. This has $50 dollars written all over it in short order.

It halted in the morning, and went as high as 18.50, a beautiful run and there is plenty of room to run still.

This is hiding behind the scenes.

This is going to get very interesting. Keep your eyes glued for an epic run, might take a few days to weeks but it will happen.

This should have a real nice run, with the dementia news, trials and the almost 16% short. Massive accumulation the last couple of weeks, a powder keg ready to blast through.

$CRVO: Almost at $14....... just $3 more to go

Wooooooooooooooo hooooooooooooooooooooooooooooooooo

How'd you like my $RGC Bagger.


Its been a great month so far !


GO $CRVO

$CRVO:: Chardan gave it a $14 PT

Woahhhhhhhhhhhhhhhhhhhh.............. I guess $10 is coming


GO $CRVO

$8.03 broke $7.98 for now see if holds solid announced positive results from the first 16 weeks of the extension phase of the Phase 2b RewinD-LB study of neflamapimod in the treatment of dementia with Lewy bodies (DLB).  
“This is a great day for patients and families impacted by DLB, as well as the DLB clinical community. The magnitude of the effect demonstrated on the CDR-SB and the CGIC, both clinically meaningful endpoints, as well the apparent beneficial effect on the incidence of participant falls, suggests that neflamapimod has the potential to fundamentally change the disease course of DLB and our approach to treating the disease,” said James E. Galvin, MD, MPH, Professor of Neurology at the Miller School of Medicine in Miami, ..

$CRVO: Now $8......... going for a 3x bagger ?????????

NO reason why it can't go past $9 now

WOOOOOOoooooooooooooooooooooooooooooooooooo


GO $CRVO

$7.58 still holding some breaks $7.98 solid off to the races see $11 next $9.58 to $11.91 a nice profit zone above 

$7.37 + 20%

Price target $14-$25.. 05:40 AM EDT, 03/13/2025 (MT Newswires) -- CervoMed (CRVO) has an average rating of overweight and mean price target of $25.57, according to analysts polled by FactSet.

CRVO................................................https://stockcharts.com/h-sc/ui?s=CRVO&p=W&b=5&g=0&id=p86431144783

#DDAmanda Video: $CRVO: Gain: +164% #1 Early Alert Stock Finder



Z

Nice day here dementia paying off  $7.25 +210%

$CRVO: Everyone sleeping on iHUB today................


She's flexing again............ showing another possible break of $6 to go to $7

GO $CRVO

$CRVO: $6.20........... Officially a BAGGER

Since first mention here almost an hour ago.

Make that money people......................... whats my NAME ???

GO $CRVO

$CRVO: Wooooooooooooooooooooooooooooooooo

Almost made it past $6 there........... woulda been nice

Maybe a slight breather.

Hot since the getgo this opening

GO $CRVO

$CRVO: You meant this March...........

Close enough........ we'll give it to ya anyways.


GO $CRVO

$CRVO: Lets crack the $5 marker

She's got the juice to make it happen

Looking good so far

GO $CRVO

$CRVO: Ok.......... now 4.40 !!!!!!!!!!

Still went up.

Who needs the rest of the market when you have sleepers like this showing fire every other day


GO $CRVO

$CRVO: She awake now after that slumber.......... $3

longgggggggggggggggggg base for 3months stretched out at $2s after that mega drop from $13 last December.

It was about time.

GO $CRVO

$2.20s some more data available Jan 2025 a few buy bites down here

Phase 2b data of dementia trial imminent expected during this month , if positive this one going to 50 dollar and more

CRVO is about to pop this DEC!!!

CRVO directionless